• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Kaleido Biosciences Inc.

    4/25/22 4:42:53 PM ET
    $KLDO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KLDO alert in real time by email
    S-8 POS 1 d344833ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on April 25, 2022

    Registration No. 333-255773

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO:

    FORM S-8 REGISTRATION STATEMENT NO. 333-255773

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    KALEIDO BIOSCIENCES, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware
      47-3048279
    (State or other jurisdiction
    of incorporation or organization)
      (I.R.S. Employer
    Identification No.)

    65 Hayden Avenue

    Lexington, MA 02421

    (Address of principal executive offices, zip code)

     

     

    Kaleido Biosciences, Inc. 2019 Stock Option and Incentive Plan

    Kaleido Biosciences, Inc. 2019 Employee Stock Purchase Plan

    (Full title of the plans)

    Kaleido Biosciences, Inc.

    65 Hayden Avenue

    Lexington, MA 02421

    (Name and address of agent for service)

    (617) 674-9000

    (Telephone number, including area code, of agent for service)

     

     

    with a copy to:

    Kingsley L. Taft

    Laurie A. Burlingame

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, MA 02210

    (617) 570-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☒

     

     

     


    DEREGISTRATION OF SHARES

    This Post-Effective Amendment (this “Amendment”) relates to the following Registration Statement on Form S-8 (the “Registration Statement”) filed by Kaleido Biosciences Inc., a Delaware corporation (the “Company”) with the Securities and Exchange Commission (the “SEC”):

     

      •  

    Registration Statement  No. 333-255773, filed on May 5, 2021, relating to the Kaleido Biosciences, Inc. 2019 Stock Option and Incentive Plan and the Kaleido Biosciences, Inc. 2019 Employee Stock Purchase Plan.

    The purpose of this Amendment is to deregister all remaining securities available for issuance under the Registration Statement. In accordance with the undertakings made by the Company in the Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering, the Company hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Boston, Massachusetts, on April 25, 2022. No other person is required to sign this Amendment in reliance upon Rule 478 under the Securities Act of 1933.

     

    KALEIDO BIOSCIENCES, INC.
    By:  

    /s/ Theo Melas-Kyriazi

    Name:   Theo Melas-Kyriazi
    Title:   Director
    Get the next $KLDO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KLDO

    DatePrice TargetRatingAnalyst
    1/31/2022$11.00 → $3.00Buy
    Chardan Capital
    11/12/2021$15.00 → $11.00Buy
    Chardan Capital
    11/3/2021$25.00 → $22.00Market Outperform
    JMP Securities
    10/19/2021$3.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings